Intracellular delivery of anti-BCR/ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells

BACKGROUND: The pathogenesis of chronic myeloid leukemia (CML) is the formation of the BCR/ABL protein, which is encoded by the bcr/abl fusion gene, possessing abnormal tyrosine kinase activity. Despite the wide application of tyrosine kinase inhibitors (TKIs) in CML treatment, TKIs drug resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Guoyun, Huang, Zhenglan, Yuan, Ying, Tao, Kun, Feng, Wenli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422775/
https://www.ncbi.nlm.nih.gov/pubmed/34488814
http://dx.doi.org/10.1186/s13045-021-01150-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422775/
https://www.ncbi.nlm.nih.gov/pubmed/34488814
http://dx.doi.org/10.1186/s13045-021-01150-x

Ejemplares similares